Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China
Biotech
Summary
The focus of the company is SERP-01, an in vivo base editing program targeting AATD developed in China and licensed from YolTech Therapeutics.
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For China, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketChina
- ImpactMedium (56/100)
- SignalFunding